Effectiveness, Durability, and Safety of Dolutegravir and Lamivudine Versus Tenofovir alafenamide, Emtricitabine, and Bictegravir in a Real-Life Cohort of HIV-Infected Adults.

Mendoza Acosta I¹, Lázaro López A¹, Martínez Ruiz E¹, Tardáguila Molina P¹, Casarrubios Lázaro G², Horta Hernandez AM¹, M. Torralba González De Suso¹. 1Guadalajara University Hospital, Pharmacy Department, Guadalajara, Spain. 2Guadalajara University Hospital, Research Department, Guadalajara, Spain.

Background and Importance

Dolutegravir plus lamivudine: initial and switch option in HIV-1 treatment. ¿Real-world studies on the effectiveness, durability and, safety of two-drug regimens (2-DR) compared to three-drug regimens (3-DR)?

Aim and Objectives

VIROLOGICAL EFFECTIVENESS + DURABILITY + SAFETY

Intention-to-treat-exposed analysis at 24 weeks in a real-life cohort of HIV-1 treatment-naive (TN) and treatment-experienced (TE) patients.

Materials and Methods

Observational and ambispective study. All TN and TE patients with 2-DR or 3-DR. Primary endpoint: % TN patients with VL<50 copies/mL. Secondary endpoints: % of patients that continued with treatment.

Materials and Methods

July 01, 2018, and September 30, 2021

Results

TN (n=27)

2-DR (74%) LogVL= 4.6 (4.1-5.1)

3-DR (26%) LogVL= 5.4 (3.9-6)

TE (n=212)

2-DR (55%) 84.6 %VL<50 copies/mL

3-DR (45%) 73.7 %VL<50 copies/mL

DURABILITY (% patients continued with treatment at week 24)

TN: 95% 2-DR Vs 93.8% of 3-DR

TE: 93.8% 2-DR Vs 91.2% of 3-DR

SAFETY (% (n) of patients that reported any AE)

Group | % VL≥50 copies/mL
--- | ---
2-DR | 20%
p=0.71
3-DR | 29%

Group | % VL<50 copies/mL
--- | ---
2-DR | 85.5%
p=0.74
3-DR | 87.5%

Conclusion and Relevance

Our results show a similar effectiveness profile of DTG plus 3TC compared with TAF/FTC/BIC at 24 weeks. Additionally, durability and safety of 2-DR were confirmed to be similar to 3-DR.

@inesmendoza91 @Farmacia_HUGU imendoza.acosta91@gmail.com